摘要
目的探讨曲妥珠单抗联合SOX化疗方案治疗人表皮生长因子受体-2(Her-2)阳性晚期胃癌疗效及对患者无进展生存期(PFS)的影响。方法选择116例Her-2阳性晚期胃癌患者,按随机对照原则分为两组,各58例。对照组给予SOX化疗方案治疗,观察组给予曲妥珠单抗联合SOX化疗方案治疗。比较两组临床疗效、毒副反应发生情况(白细胞减少、中性粒细胞减少、血小板减少、贫血、恶心、呕吐、黏膜炎)及PFS。结果治疗后,观察组客观缓解率(RR)、疾病控制率(DCR)分别为67.24%、89.66%,均高于对照组48.28%、72.41%,差异有统计学意义(P<0.05);治疗期间,两组毒副反应发生率比较差异无统计学意义(P>0.05);观察组PFS时间较对照组长,差异有统计学意义(P<0.05)。结论曲妥珠单抗联合SOX化疗方案能够有效提升治疗Her-2阳性晚期胃癌的临床疗效,延长患者PFS时间,同时未明显增加毒副反应,安全性较高,值得临床推广。
Objective To investigate the efficacy of trastuzumab combined with Sox chemotherapy in the treatment of advanced gastric cancer with positive human epidermal growth factor receptor-2(HER-2)and its effect on progression free survival(PFS).Methods 116 patients with HER-2 positive advanced gastric cancer were randomly divided into two groups,58 cases in each group.The control group was given Sox chemotherapy,and the observation group was given trastuzumab combined with Sox chemotherapy.The clinical efficacy,adverse reactions(leucopenia,neutropenia,thrombocytopenia,anemia,nausea,vomiting,mucositis)and PFS were compared between the two groups.Results After treatment,the objective remission rate(RR)and disease control rate(DCR)of the observation group were 67.24%and 89.66%,respectively,which were higher than 48.28%and 72.41%of the control group,the difference was statistically significant(P<0.05);during the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);the PFS time in the observation group was longer than that in the control group,the difference was statistically significant(P<0.05).Conclusion Trastuzumab combined with Sox chemotherapy regimen can effectively improve the clinical efficacy of the treatment of HER-2 positive advanced gastric cancer,prolong the PFS time of patients,and do not significantly increase the toxicity and side effects,which is worthy of clinical promotion.
作者
焦阳
Jiao Yang(Department of Pharmacy,Kaifeng Cancer Hospital,Kaifeng475000,China)
出处
《哈尔滨医药》
2021年第6期16-18,共3页
Harbin Medical Journal
